Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arrowhead Pharmaceuticals, Inc.    ARWR

ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/10/2020 02/11/2020 02/12/2020 02/13/2020 02/14/2020 Date
42.85(c) 41.58(c) 42.41(c) 41.05(c) 41.27(c) Last
1 577 207 1 254 552 1 020 641 946 004 1 032 392 Volume
+5.99% -2.96% +2.00% -3.21% +0.54% Change
More quotes
Financials (USD)
Sales 2020 95,9 M
EBIT 2020 -40,1 M
Net income 2020 -35,2 M
Debt 2020 -
Yield 2020 -
Sales 2021 115 M
EBIT 2021 -45,9 M
Net income 2021 -79,3 M
Debt 2021 -
Yield 2021 -
P/E ratio 2020 -117x
P/E ratio 2021 -53,0x
Capi. / Sales2020 43,7x
Capi. / Sales2021 36,4x
Capitalization 4 195 M
More Financials
Company
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference... 
More about the company
Surperformance© ratings of Arrowhead Pharmaceuticals,
Trading Rating : Investor Rating :
More Ratings
Latest news on ARROWHEAD PHARMACEUTICALS,
02/05ARROWHEAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
02/05ARROWHEAD PHARMACEUTICALS, INC. : Results of Operations and Financial Condition,..
AQ
02/05ARROWHEAD PHARMACEUTICALS : Reports Interim Clinical Data on Cardiometabolic Can..
BU
02/05ARROWHEAD PHARMACEUTICALS : Reports Fiscal 2020 First Quarter Results
BU
01/22ARROWHEAD PHARMACEUTICALS : to Webcast Fiscal 2020 First Quarter Results
BU
01/16Purcell Julie & Lefkowitz LLP Is Investigating Arrowhead Pharmaceuticals, Inc..
PR
01/06ARROWHEAD PHARMACEUTICALS : Appoints James Hassard as Chief Commercial Officer
BU
2019ARROWHEAD PHARMACEUTICALS : Doses First Patient in AROAAT2002 Open Label Phase 2..
AQ
2019ARROWHEAD PHARMACEUTICALS : Doses First Patient in AROAAT2002 Open Label Phase 2..
BU
2019ARROWHEAD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (for..
AQ
2019ARROWHEAD PHARMACEUTICALS : Reports Inducement Grants under NASDAQ Marketplace R..
AQ
2019ARROWHEAD PHARMACEUTICALS : Reports Inducement Grants under NASDAQ Marketplace R..
BU
2019ARROWHEAD PHARMACEUTICALS : Appoints Marianne De Backer to Board of Directors
AQ
2019ARROWHEAD PHARMACEUTICALS : Files for Regulatory Clearance to Begin Phase 1 Stud..
BU
2019ARROWHEAD PHARMACEUTICALS : Appoints Marianne De Backer to Board of Directors
BU
More news
News in other languages on ARROWHEAD PHARMACEUTICALS,
2019ARROWHEAD PHARMACEUTICALS INC : Veröffentlichung des Halbjahresergebnisses
2019ARROWHEAD PHARMACEUTICALS INC : publication des résultats semestriels
2018ARROWHEAD PHARMACEUTICALS INC : Veröffentlichung des Jahresergebnisses
2018ARROWHEAD PHARMACEUTICALS INC : publication des résultats annuels
2018WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on ARROWHEAD PHARMACEUTICALS,
More recommendations
Sector news : Bio Therapeutic Drugs
12:42aGilead's Coronavirus Drug Trial Slowed Due to Lack of Eligible Recruits
DJ
02/12Coronavirus-Drug Development Becomes a Top Focus at Gilead
DJ
02/12GILEAD SCIENCES : Correction to Report About Gilead Sciences' Work on a Coronavi..
DJ
02/12Gilead Sciences Scrambles to Supply Experimental Coronavirus Drug
DJ
02/11NOVARTIS, INCYTE : Capmatinib Gets FDA Priority Review
DJ
More sector news : Bio Therapeutic Drugs
Chart ARROWHEAD PHARMACEUTICALS, INC.
Duration : Period :
Arrowhead Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARROWHEAD PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 64,50  $
Last Close Price 41,27  $
Spread / Highest target 101%
Spread / Average Target 56,3%
Spread / Lowest Target -24,9%
EPS Revisions
Managers
NameTitle
Christopher Richard Anzalone President, Chief Executive Officer & Director
Douglass B. Given Chairman
Bruce D. Given Chief Operating Officer
Kenneth Allen Myszkowski CFO & Principal Accounting Officer
James C. Hamilton Vice President & Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ARROWHEAD PHARMACEUTICALS, INC.-34.94%4 195
GILEAD SCIENCES3.97%85 473
VERTEX PHARMACEUTICALS11.36%63 215
REGENERON PHARMACEUTICALS6.41%43 494
WUXI APPTEC CO., LTD.23.75%26 838
GENMAB10.53%15 457